South Asian Journal of Cancer最新文献

{"title":"Prognostic Significance of Chemotherapy Response Score in Patients Undergoing Interval Debulking Surgery and Attained Complete Cytoreduction for High-Grade Serous Tubal and Ovarian Carcinoma.","authors":"Anjana J Santhamma, Suchetha Sambasivan, Simi C Mohanan, Rema Prabhakaran Nair, Siva Ranjith J, Francis V James, Reba Ann Zachariah, Jagathnath Krishna K Mohanan Nair","doi":"10.1055/s-0044-1791834","DOIUrl":"10.1055/s-0044-1791834","url":null,"abstract":"<p><strong>Objectives: </strong>The chemotherapy response score (CRS) has been described to assess the pathological response to chemotherapy in patients with high-grade serous tubal and ovarian carcinoma. The main aim of this study was to assess the prognostic significance of CRS in patients who underwent interval debulking surgery and attained complete cytoreduction.</p><p><strong>Materials and methods: </strong>A retrospective study was conducted on patients with Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage IIIC and IV high-grade serous tubal and ovarian carcinomas who had undergone surgery after three to four cycles of neoadjuvant chemotherapy and attained complete cytoreduction from January 2015 to July 2018.</p><p><strong>Results: </strong>A total of 125 patients were included in the study. The median age of the patients was 52 years. There were 21 patients (16.8%) with a CRS of 1, 53 patients (42.4%) with a CRS of 2, and 51 (40.8%) patients with a CRS of 3. The median follow-up period was 77 months. The CRS applied on the omental samples showed significant correlation with progression-free survival (PFS; CRS of 1 vs. 2: median PFS, 17 vs. 22 months; hazard ratio, 1.73; and CRS of 2 vs. 3: median PFS, 22 vs. 54 months; hazard ratio, 2.32) and overall survival (OS; CRS of 1 vs. 2: median OS, 19 vs. 40 months; hazard ratio, 2.13; CRS of 2 vs. 3: median OS, 40 months vs. not reached; hazard ratio, 2.19).</p><p><strong>Conclusion: </strong>Our study confirms that the omental CRS is significantly associated with PFS and OS in patients who attained complete cytoreduction during interval debulking surgery.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 3","pages":"474-479"},"PeriodicalIF":0.8,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12727004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145828466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC).","authors":"Purvish M Parikh, Ghanashyam Biswas, Nilesh Ashok Dhamne, Chetan Dilip Deshmukh, Sewanti Limaye, Ashish Singh, Hemant Malhotra, Viashsta Pankaj Maniar, Bhupendra Nath Kapur, Prasad V S S Sripada, Vikas Tulsidas Talreja, Poonam Patil, Suhas Vilasrao Agre, Amit Dilip Bhat, Priya Privadarshini Nayak, Arun Seshachalam, Boman Nariman Dhabhar, Ajay Sharma, Niraj N Bhatt, Pratap Kishore Das, Atul Sharma, Govind Babu Kanakasetty, Suresh Hariram Advani","doi":"10.1055/s-0044-1791783","DOIUrl":"10.1055/s-0044-1791783","url":null,"abstract":"<p><p>Head and neck squamous cell carcinoma (HNSCC) is the most common malignancy group in India and several other low- and middle-income countries. Currently, majority of the patients present in advanced stage where systemic therapy is standard of care. Multiple relapses are also not uncommon. Almost all HNSCC tumors have epidermal growth factor receptor (EGFR) overexpression, making an attractive target. Cetuximab is the most successful method to target EGFR in HNSCC. After decades of its use, it still is a prominent part of the current management guidelines. Since other agents have also been proven to be useful, we felt it was necessary to develop a real-world consensus guideline to help the decision-making process among the community oncologists. Our expert committee therefore put together currently available data, insights from their real-world clinical practice, and voted to arrive at a consensus. These consensus guidelines represent how cetuximab should be used today in the management of HNSCC.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 1","pages":"90-102"},"PeriodicalIF":0.6,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Pediatric Renal Tumors over 5 Years in Regional Cancer Center, Kidwai Memorial Institute of Oncology, Bengaluru, South India.","authors":"Sathya Murugasamy, Lingegowda Appaji, Arun Kumar, Nuthan Kumar, Prakruthi S Kaushik, Mohana Reddy, Avinash Thumallapalli, Bangegadde S Aruna Kumari","doi":"10.1055/s-0044-1789580","DOIUrl":"10.1055/s-0044-1789580","url":null,"abstract":"<p><p>Wilms' tumor (WT) is the most common malignant renal tumor in the pediatric population and it is managed with a multimodal treatment. Improvements in chemotherapy and risk stratification have led to dramatic improvement in the prognosis of renal tumors, which was once a lethal malignancy. Seventy-three patients with histopathologically proven diagnosis of renal tumor who received treatment from January 2011 to December 2015 were included for analysis. Eight children underwent upfront nephrectomy. The patients were analyzed for event-free survival and overall survival. The outcomes were correlated with age, sex, stage at presentation, and histology. A favorable histology was found in 74% patients, while an unfavorable histology was observed in 26% of the cases. The 5-year event-free survival was 82.7% and overall survival was 87.6%. The stage at presentation had a prognostic value ( <i>p</i>  < 0.001). Tumor histology was the single most important factor in predicting the survival.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 3","pages":"551-554"},"PeriodicalIF":0.8,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12727032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145828437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Patient Wait Times on the First Day of Radiotherapy Treatment.","authors":"Rahul Krishnatry, Naveen Mummudi, Sarbani Ghosh Laskar, Jayita Deodhar, Vivek Vasant Sutar, Avdhoot Balaso Sutar, Michelle Aileen DeNatale, Ruby Daniel Nadar, Shibu James, Rajesh Ashok Kinhikar, Jai Prakash Agarwal","doi":"10.1055/s-0043-1771408","DOIUrl":"10.1055/s-0043-1771408","url":null,"abstract":"<p><p>Long wait times on starting day of radiotherapy (day 1) can cause dissatisfaction among both patients and healthcare providers. Reducing these wait times will decrease stress and decongest hospital facilities especially in current coronavirus disease 2019 times. A multidisciplinary core team was formed during the Stanford-India Collaborative Quality Improvement training to reduce the median wait times on day 1 of treatment from 6 to 4.5 hours (a 25% reduction). Several factors were identified on the fishbone diagram, and key causes were identified using a Pareto chart and action prioritization matrix. The Plan-Do-Study-Act Cycle strategy was undertaken for the identified interventions. The outcome measure was time from arrival at the hospital to entry into a treatment room. Data were obtained from time charts at various stations and electronic records. The secondary measures were visual analog scale (VAS) scores, 80th percentile wait times, and the day-2 delay percentage. The balancing measure was \"new errors\" due to interventions. The interventions included the completion of all administrative tasks not needing patients' presence on the day before day 1. Baseline data from 198 patients and postintervention data from 160 patients were compared and analyzed. The median wait time at baseline, which was 6 hours, was reduced to 4.2 hours. The VAS score showed 70.4, 67.7, and 71.9% satisfaction for the resident physician, therapists, and patients, respectively. The 80th percentile wait times reduced from 8 to 5.7 hours; and the day 2 starting rate decreased from 22.5 to 2.04%, with no new errors reported. Radiotherapy day 1 wait times can be safely decreased, leading to improved satisfaction among patients and healthcare providers, by utilizing classic quality improvement methods and tools.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 4","pages":"827-831"},"PeriodicalIF":0.8,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12747739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145864707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liposomal AZD5363 Displays Antiproliferation Activities and Induces Apoptosis on Y79 Retinoblastoma Cancer Cells.","authors":"Zahra Khabazian, Nafiseh Esmaeil, Maryam Khanehzad, Amir Hossein Naderi Majd, Mahdi Tohidian, Giti Zarinfard","doi":"10.1055/s-0044-1791264","DOIUrl":"10.1055/s-0044-1791264","url":null,"abstract":"<p><strong>Objectives: </strong>Retinoblastoma (RB) is an aggressive intraocular cancer that usually develops during infancy and childhood. As an Akt kinase inhibitor, AZD5363 is a novel drug whose encapsulation into liposomes enhances its bioavailability and biomedical potential. In the present study, a liposomal membrane was created around AZD5363 to assess its efficacy on the Y79 cancer cell line.</p><p><strong>Materials and methods: </strong>AZD5363 nanoparticles were synthesized by the thin film hydration method. Dynamic light scattering (DLS) and field emission scanning electron microscopy (FESEM) techniques were applied to evaluate the particle size, and the morphology of the liposomal AZD5363 (Lipo-AZD5363). The MTT test was used to assess the half maximal inhibitory concentration (IC50) of Lipo-AZD5363, and the cytotoxic effects of Lipo-AZD5363 and doxorubicin (Dox) were investigated on the Y79 cell line. Flow cytometry was used to study apoptotic induction in selected groups. Also, the <i>PTEN/AKT/FOXO1</i> gene expression level was measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay.</p><p><strong>Results: </strong>Treatment with Lipo-AZD5363 inhibited the proliferation of Y79 RB cancer cell line in a dose-dependent manner. Lipo-AZD5363, at a lower concentration, was significantly more cytotoxic than Dox in terms of enhanced cell death ( <i>p</i>  < 0.05). Furthermore, flow cytometry showed that Lipo-AZD5363 and Dox induce apoptosis in these cells. However, the number of apoptotic cells in the Lipo-AZD5363 group was clearly higher than that in the Dox group ( <i>p</i>  < 0.001). Real-time PCR analysis indicated that Lipo-AZD5363 treatment resulted in an increase in <i>PTEN</i> and <i>FOXO1</i> gene expression and a decrease in <i>AKT</i> gene expression. Our study revealed that all results were statistically more significant in the Lipo-AZD5363 group than in the Dox group ( <i>p</i>  < 0.01, <0.01, and <0.001, respectively).</p><p><strong>Conclusion: </strong>Lipo-AZD5363 inhibits proliferation and promotes apoptosis of RB cells by inhibiting the PI3K/AKT signaling pathway. Thus, Lipo-AZD5363 may be a promising candidate for cancer therapy. However, more experimental evidence is needed for its use in the pharmacological treatment of RB.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 4","pages":"760-764"},"PeriodicalIF":0.8,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12747735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145864833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of First-Line Palliative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel (FLOT) in HER2-Negative Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Institutional Real-World Experience from Eastern India.","authors":"Tamojit Chaudhuri, Jaishree Bankira, Amitabh Kumar Upadhyay, Rahul Panda, Vanita Pandey, Sujata Mitra, Sopia Mukherjee","doi":"10.1055/s-0044-1791524","DOIUrl":"10.1055/s-0044-1791524","url":null,"abstract":"<p><strong>Background: </strong>Fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) is one of the preferred perioperative chemotherapy regimens in locally advanced resectable gastric cancer (GC). Till date, there are very few published data from India, regarding the outcomes of this relatively well-tolerated biweekly triplet regimen as first-line palliative chemotherapy in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.</p><p><strong>Materials and methods: </strong>In the present retrospective study, we evaluated the efficacy and safety of first-line FLOT regimen in Indian patients with HER2-negative metastatic adenocarcinoma of stomach or GEJ. The primary endpoint was overall survival (OS). Progression-free survival (PFS), overall response rate (ORR), and toxicity profile were taken as secondary endpoints.</p><p><strong>Results: </strong>Between January 2021 and June 2024, 88 patients were treated with FLOT. The median age was 52 years (range, 23-68); 69.3% were males and 37.5% of the patients had ≥ 3 metastatic disease sites involvement at baseline. Dose reductions due to toxicity were required in 25% of the patients. The ORR was 68.2%; median PFS and OS were 6.3 months (95% confidence interval [CI]: 5.3-7.4) and 12.5 months (95% CI: 11.3-14.2), respectively. The most frequent grade 3 to 4 adverse events were diarrhea (15.9%), fatigue (13.6%), and neutropenia (12.5%). Younger patients (aged < 55 years) had much less ≥ grade 3 diarrhea (7.5%, <i>n</i>  = 4), compared with patients aged ≥ 55 years (28.6%, <i>n</i>  = 10). There was one toxicity-related death.</p><p><strong>Conclusion: </strong>In the present study, biweekly FLOT regimen with primary prophylactic granulocyte colony-stimulating factor demonstrated encouraging efficacy with a favorable nongastrointestinal toxicity profile in Indian patients with HER2-negative metastatic gastric or GEJ adenocarcinoma. Clearly, this well-tolerated triplet regimen should be explored further through large prospective randomized trials in Asian patients.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 2","pages":"265-270"},"PeriodicalIF":0.8,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12714477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145805380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roadmap to Success: Illustrating Insights from a KAP Study on Cervical Cancer Prevention and HPV Vaccination.","authors":"Priya Ganeshkumar, Jaydeep Tank, Saswati Sanyal Choudhury, Veena Acharya, Yashodhara Gaur, Reena Srivastava, Revathy Janakiraman, Akshay Ganeshkumar","doi":"10.1055/s-0044-1791523","DOIUrl":"10.1055/s-0044-1791523","url":null,"abstract":"<p><strong>Introduction: </strong>Cervical cancer is a public health challenge in low- and middle-income countries, with India ranking among the highest in cervical cancer burden. The World Health Organization (has set ambitious targets for cervical cancer elimination by 2030, emphasizing the importance of human papillomavirus (HPV) vaccination and screening. In response, the National Technical Advisory Group of Immunization recommends the introduction of HPV vaccination for all eligible girls aged 9 to 14 years in India under the Universal Immunization Program. However, successful implementation requires both vaccine availability and changes in health care providers' knowledge, attitudes, and practices (KAP) regarding cervical cancer prevention and HPV vaccination.</p><p><strong>Methodology: </strong>This study aims to assess KAP among clinicians regarding cervical cancer and HPV vaccination. A cross-sectional survey collected responses from 451 practicing gynecologists and medical practitioners across 15 states of India. The questionnaire sought insights into patient inquiries, information sources, awareness levels, methods of patient education, and common myths and misconceptions.</p><p><strong>Results: </strong>Results indicate a high prevalence of patient inquiries about cervical cancer and the HPV vaccine, emphasizing the need for accurate and accessible information. While doctors were generally knowledgeable, misconceptions persisted among patients, including beliefs about low risk, inevitability of cervical cancer, and concerns about vaccine safety. Doctors primarily relied on verbal communication for patient education, suggesting potential for utilizing digital platforms and visual aids to enhance outreach.</p><p><strong>Insights: </strong>Insights from doctors underscored the importance of addressing misinformation and leveraging various communication channels, including social media, posters, and celebrity endorsements, to improve awareness and acceptance of vaccination. Disparities in vaccine availability and administration rates highlighted the need for targeted interventions to ensure equitable access.</p><p><strong>Limitations: </strong>Limitations of the study included its cross-sectional design and reliance on self-reported data, which may introduce bias. However, findings suggest a need for ongoing medical education and collaboration with stakeholders to drive awareness and acceptance of HPV vaccination.</p><p><strong>Conclusion: </strong>In conclusion, while gynecologists and medical practitioners demonstrate adequate KAP regarding cervical cancer prevention, there is room for improvement in patient education and communication strategies. Refining educational materials and strengthening communication channels would enhance awareness and reduce cervical cancer burden.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 3","pages":"431-438"},"PeriodicalIF":0.8,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12727005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145828462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prevalence of Cytogenetic Abnormalities Detected by Interphase FISH Method in Chronic Lymphocytic Leukemia.","authors":"Shirin Azhdari, Sadat Noori, Khosrow Daneshbod, Abolfazl Khalafi-Nezhad, Seyed Mohammad Ali Hashemi, Zahra Faghih, Shirin Haghighat, Jamal Sarvari","doi":"10.1055/s-0044-1790543","DOIUrl":"10.1055/s-0044-1790543","url":null,"abstract":"<p><strong>Background: </strong>Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia. Identification of genomic aberration provides prognostic/predictive information that is helpful in the precision medicine management of these patients. The aim of this study was to determine prevalence of the most common cytogenetic abnormalities of CLL patients in the southwest region (Shiraz) of Iran and correlate with clinical prognostic parameters to clarify their prognostic value.</p><p><strong>Materials and methods: </strong>In this cross-sectional study, 100 patients with CLL were recruited from April 2019 to October 2021. Four milliliters of anticoagulated peripheral blood was collected from each participant. The sample was used for complete blood count (CBC) test and fluorescence in situ hybridization (FISH) test. Interphase FISH (I-FISH) was performed for most common cytogenetic abnormalities, including trisomy 12, 13q14 deletion, 11q deletion, and 17p deletion on interphasic cell nuclei.</p><p><strong>Results: </strong>Among 100 patients with CLL, 33 (33%) were females and 67 (67%) were males. The mean age (mean ± standard error [SE]) of the patients was 59.00 ± 1.14 years, with a ranged of 25 to 79 years. Our analysis demonstrated that 86 (86%) patients had at least one chromosomal aberration. The most commonly detected abnormality was 13q deletion (61, 61%), followed by 17q deletion (50 cases, 50%). Trisomy 12 was detected in 14 (14%) cases and 10 cases (10%) had 11q deletion.</p><p><strong>Conclusion: </strong>The higher frequency of 13q14 and 17p anomalies in our study may be attributed to delayed medical consultations, leading to the emergence of secondary abnormalities. More studies are recommended for verifying the results.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 3","pages":"601-607"},"PeriodicalIF":0.8,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12727008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145828430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Long-Term Outcomes of Thymoma Treated at a Single Institute.","authors":"Sorun Shishak, Tejinder Kataria, Shyam Singh Bisht, Susovan Banerjee, Deepak Gupta, Venkatesan Kaliyaperumal, Kushal Narang, Mayur Mayank, Rajesh Selvaraj, Susan K Abraham, Shikha Goyal","doi":"10.1055/s-0044-1791272","DOIUrl":"10.1055/s-0044-1791272","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1055/s-0044-1788257.].</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 2","pages":"e1"},"PeriodicalIF":0.7,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13120850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147781439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility, Safety, and Factors Predicting Completion of CROSS Protocol-Based Neoadjuvant Chemoradiotherapy for Esophageal Squamous Carcinoma: Experience from an Indian Tertiary Care Cancer Center.","authors":"Suraj Surendran, Geet Midha, Manu Mathew, Rajesh Isiah, Negine Paul, Myla Yacob, Balu Krishna Sasidharan, Simon Pavamani, Sudhakar Chandran, Vijay Abraham, Subhashini John, Thenmozhi Mani, Inian Samarasam","doi":"10.1055/s-0044-1789275","DOIUrl":"10.1055/s-0044-1789275","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemoradiotherapy (NACRT) using the ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) protocol has improved esophageal cancer outcomes. This study reports the real-world experience of the CROSS regimen for esophageal squamous cell carcinoma (ESCC) regarding its feasibility, safety, and predictors of treatment completion from an Indian tertiary center.</p><p><strong>Methodology: </strong>A retrospective review was conducted for patients with ESCC receiving CROSS (radiation dose: 41.4 Gy) or a modified CROSS (mCROSS; radiation dose: 45 Gy) protocol NACRT between 2015 and 2022. We studied the treatment tolerability, factors predicting NACRT completion, and the effect of completion of its chemotherapy component on the pathological outcomes.</p><p><strong>Results: </strong>Of the109 patients (68.8% males; mean age, 56 ± 9 years; Charlson's comorbidity index [CCI] >2, 19.3%; stage III-IVA, 58%; mean tumor length, 5.5 ± 2.1cm; CROSS, 70.6%; mCROSS, 29.4%), all except 4 completed radiotherapy but only 58 (53.2%) patients completed ≥4 cycles of chemotherapy. Forty-nine patients belonged to the \"extended\" CROSS trial inclusion criteria. Among the 60 patients who fulfilled the CROSS inclusion criteria, only 51.7% were able to complete ≥4 chemotherapy cycles. The commonest reason for noncompletion of chemotherapy was the occurrence of neutropenia (60.8%). Pretreatment hemoglobin (≥12 vs. <12 g%; odds ratio [OR]: 2.76; 95% confidence interval [CI]: 1.10-6.96; <i>p</i>  = 0.031), a low CCI (≤2 vs. >2; OR: 2.98; 95% CI: 1.02-8.73; <i>p</i>  = 0.047), and radiation therapy techniques (conformal vs. conventional; OR: 3.29; 95% CI: 1.14-9.50; <i>p</i>  = 0.028) were associated with completion of chemotherapy (≥4 cycles). Although there was a trend toward improved R0 resection (95.7 vs. 91.4%), reduced node positivity (17.0 vs. 31.4%), and a high pCR (57.4 vs. 48.6%) in patients completing chemotherapy (≥4 cycles) compared with those not completing chemotherapy (<4 cycles), these differences were statistically nonsignificant.</p><p><strong>Conclusion: </strong>In this study, ESCC patients receiving the CROSS protocol NACRT could complete their radiotherapy component, but a significant proportion exhibited poor chemotherapy tolerance. Neutropenia was a major factor limiting chemotherapy delivery, but anemia, high CCI, and conventional radiation techniques were also associated with noncompletion of chemotherapy. The omission of a few chemotherapy cycles had no significant effect on the pathological response; however, its impact on cancer survival requires further evaluation.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 2","pages":"290-300"},"PeriodicalIF":0.8,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12714434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145805395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}